Fresenius Medical Care: Is Trading Below Its Intrinsic Value (Buy)

Fresenius Medical Care (FMS) is rated a "Buy," with shares up 32.95% year-over-year and Q1 2025 net income growing 60%. Valuation suggests FMS is over 130% undervalued, projecting a $62.06 share price by 2026, supported by a superior 3.07% dividend yield compared to peers. Despite risks from high revenue costs impacting profitability, the company's focus on top-line growth underpins its position as an attractive value play with significant potential upside.

Analysis

The article presents a strong bullish case for Fresenius Medical Care (FMS), labeling it a "Buy" based on significant recent performance and perceived undervaluation. The company's shares have appreciated 32.95% year-over-year, supported by robust Q1 2025 results that featured a 60% year-over-year increase in net income. The core of the investment thesis rests on a valuation model using a forward price-to-sales ratio, which suggests the stock is trading at a discount of over 130% to its intrinsic value, leading to a projected 2026 share price of $62.06. FMS is also positioned favorably against its peers due to a superior 3.07% dividend yield and higher potential upside. However, the analysis acknowledges a key risk factor: high costs of revenue that could pressure profitability and the sustainability of the dividend. The author, who discloses a long position in the stock, believes the company's focus on top-line growth mitigates this risk.

Key Decisions for Investors

• Given the reported 60% YoY net income growth and a valuation model suggesting significant upside, value-oriented investors may find FMS an attractive candidate for further due diligence.
• For those seeking income, the 3.07% dividend yield is notable, but this should be assessed in conjunction with the identified risk that high revenue costs could impact future profitability and payout sustainability.
• It is crucial for investors to monitor the company's cost management and profit margins in upcoming quarters, as this is the primary headwind cited against the bullish thesis.
• Investors should note the analyst's disclosed long position in FMS, which indicates a potential bias in the highly optimistic price target and "Buy" rating.